Biome Unveils Activated Therapeutics with Four Targeted Natural Medicines
Biome Australia is expanding its health portfolio with Activated Therapeutics, a new practitioner-only brand launching four evidence-based natural medicine products in Q4 2025.
- Launch of Activated Therapeutics brand alongside Activated Probiotics
- Four new products targeting perimenopause, gut repair, acid reflux, and weight management
- Focus on evidence-based, microbiome-centered natural medicines
- Practitioner-only distribution model to support health professionals
- Products designed to complement pharmaceutical treatments and fill market gaps
Biome Broadens Therapeutic Reach
Biome Australia Limited (ASX: BIO) is set to launch Activated Therapeutics, a new brand complementing its flagship Activated Probiotics range. Scheduled for release in the fourth quarter of 2025, this initiative marks a strategic expansion beyond probiotics into a broader spectrum of natural medicines. The company aims to leverage its microbiome expertise to address unmet health needs with evidence-based formulations.
Four Targeted Products with Clinical Backing
The Activated Therapeutics line will debut with four specialised products: Oestro-ISO for perimenopause symptom relief, Synbio-GOS for gastrointestinal repair, Pepti-BIOTIC targeting acid reflux, and Macro-PRO, a plant-based meal replacement supporting weight management and nutritional needs, including for patients on GLP-1 medications. Each product is formulated with natural ingredients and backed by scientific research, reflecting Biome’s commitment to evidence-based innovation.
Practitioner-Only Distribution to Enhance Patient Outcomes
Positioned exclusively for health practitioners and behind-the-counter pharmacy sales, Activated Therapeutics aims to empower healthcare providers with effective natural medicine options. This approach supports better patient outcomes through tailored, practitioner-guided use, while also opening new co-prescribing opportunities alongside conventional pharmaceuticals, such as proton pump inhibitors for acid reflux.
Strategic Market Positioning and Growth Potential
Biome’s Managing Director, Blair Vega Norfolk, highlighted the timing and strategic value of the launch, noting the company’s strong foundation in microbiome science and probiotic education. The new brand addresses significant market demand, particularly in women’s health and gut-related conditions, and is designed to fill gaps in the complementary medicine sector. Early feedback from health practitioner and pharmacy networks has been positive, suggesting promising commercial prospects.
Activated Therapeutics represents a thoughtful extension of Biome’s mission to prevent disease and improve quality of life through natural, scientifically supported products. The company’s focus on practitioner engagement and evidence-based formulations positions it well to capture emerging opportunities in the evolving health and wellness landscape.
Bottom Line?
Activated Therapeutics could redefine Biome’s market footprint, but its success hinges on practitioner adoption and patient outcomes.
Questions in the middle?
- How quickly will health practitioners integrate Activated Therapeutics into their treatment protocols?
- What competitive responses might emerge from other complementary medicine providers?
- Will Biome expand Activated Therapeutics beyond the initial four products and into new therapeutic areas?
